Leerink Partnrs Has Negative Outlook of PRCT Q2 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs dropped their Q2 2025 EPS estimates for PROCEPT BioRobotics in a note issued to investors on Monday, April 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.43) for the quarter, down from their previous estimate of ($0.39). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.54) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.23) EPS and FY2029 earnings at $0.23 EPS.

Several other research firms have also weighed in on PRCT. Morgan Stanley reduced their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Bank of America decreased their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating for the company in a report on Friday, April 25th. Finally, Truist Financial dropped their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, April 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.00.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $52.85 on Thursday. The stock has a market capitalization of $2.92 billion, a P/E ratio of -27.10 and a beta of 1.09. The business has a 50-day moving average of $56.89 and a two-hundred day moving average of $73.47. PROCEPT BioRobotics has a fifty-two week low of $47.04 and a fifty-two week high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. PROCEPT BioRobotics’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.51) EPS.

Insider Activity at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares of the company’s stock, valued at $9,875,374.20. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 in the last ninety days. 17.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of hedge funds have recently made changes to their positions in the business. CWM LLC raised its position in PROCEPT BioRobotics by 69.5% in the first quarter. CWM LLC now owns 873 shares of the company’s stock worth $51,000 after purchasing an additional 358 shares in the last quarter. New York State Common Retirement Fund lifted its position in shares of PROCEPT BioRobotics by 8.6% during the 1st quarter. New York State Common Retirement Fund now owns 205,495 shares of the company’s stock worth $11,972,000 after buying an additional 16,341 shares during the period. Arizona State Retirement System boosted its stake in PROCEPT BioRobotics by 3.2% in the 1st quarter. Arizona State Retirement System now owns 14,737 shares of the company’s stock valued at $859,000 after buying an additional 452 shares in the last quarter. Alps Advisors Inc. raised its stake in PROCEPT BioRobotics by 41.6% during the first quarter. Alps Advisors Inc. now owns 14,828 shares of the company’s stock worth $864,000 after acquiring an additional 4,353 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in shares of PROCEPT BioRobotics by 32.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $64,000 after purchasing an additional 270 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).